[The modulator effect of bradykinin with respect to tracheobronchial clearance in healthy subjects]

What Was Tested

The paper reports a study of Bradykinin, published as a randomized controlled trial.

A study was carried out in order to evaluate the effect of inhaled Bk on tracheobronchial clearance (TBC), measured by a radioaerosol technique in 10 healthy volunteers.

Why It Was Studied

Bradykinin (Bk), a vasoactive nonapeptide which has been proposed as mediator in the pathogenesis of bronchial asthma, is a potent secretagogue in canine airways and in human nasal mucosa in vivo.

Who Took Part

According to the abstract, 10 volunteers were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Bradykinin and who got the comparison, which limits bias.

Neither the volunteers nor the staff measuring them knew who was on Bradykinin, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Bradykinin could be set against what happens without it.

What Was Measured

Topics PubMed links to this paper include Aerosols, Bradykinin, Bronchi, Mucociliary Clearance, Respiratory Function Tests, Technetium and Trachea.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Bradykinin in 10 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1992 (Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna), a journal based in Italy.

More context: the Bradykinin compound page, all human trials.